of Diseases Treated by
Treatment of Down Syndrome, and Other Genetic and Chromosomal Diseases, and Serious Diseases of Childhood such as Autism, by BCRO Fetal Precursor Cell Transplantation
One out of 50 live newborns has a serious congenital disease, in one out of 100 it is a genetic disorder and in one out of 200 a chromosomal disease.
Medical textbooks state that genetic and chromosomal diseases have no known treatment. There have been many publications from the university hospitals of Germany, France, U.S.S.R./Russia, Spain, etc. that report on the success in the treatment of many genetic and chromosomal diseases by BCRO fetal precursor cell transplantation, so that therapeutic nihilism is not justified whatsoever.
80+ years of existence of fetal precursor cell transplantation has proved otherwise. In principle all genetic and chromosomal diseases are treatable with fetal precursor cell transplantation but the treatment must be started without delay after the diagnosis was made.
There are several thousand genetic disease known to medicines, and many variants thereof, and only a very few of them have known treatment. Some of them have been treated with BCRO fetal precursor cell transplantation with success, but many others, particularly the rare ones, not yet, because no one has attempted to do it. Or at least no medical report has been written about it. Since unfortunately, animal models of 99.9% of human genetic and chromosomal diseases do not exist, and BCRO fetal precursor cell transplantation is known to be safer than taking an appropriate dose of aspirin, providing that fetal precursor cell transplants have been prepared properly, such approach is not harmful to the patient even if treated right after birth. That much more when the complication rate has been a perfect zero,
A physician can learn about the benefit of BCRO fetal precursor cell transplantation for the treatment of a specific child with a rare genetic disease only by trial and error. There is no harm in trying to do so. There are only two possible outcomes: either there will be an improvement, or there will be no change in the condition of patient. Under no circumstances will there be a worsening.
If there is no therapeutic response, then BCRO fetal precursor cell transplantation is not repeated. If there is a positive response, then the treatment is carried out every 4 months as long as the clinical response is to the satisfaction of the treating physician and most importantly of parents who are usually the best judges of therapeutic success.
We have called this a clinical trial of one, where the patient himself is the tested subject and his response to BCRO fetal precursor cell transplantation was the basis of the decision about the future treatment of this patient.
There are only two options: either the patient will get better or there will be no improvement. There has never been a patient whose condition worsened in BCRO clinical experience of 26 years, and 60+ years when looking at German publications.
The degree of therapeutic success depends upon the quantity and quality of data about the genetic or chromosomal disease to be treated by BCRO fetal precursor cell transplantation. The better is our knowledge of that disease in general, and in that specific patient in particular, and the sooner after the birth is BCRO fetal precursor cell transplantation carried out, the greater is the chance of success.
Currently the main problem is a lack of education of parents of such ill children, which causes a delayed start of treatment.
Genetic and chromosomal diseases of central nervous system must be treated by fetal precursor cell transplantation before reaching the age of 4 years. When dealing with genetic and chromosomal diseases of the remaining 14 organ systems the rule that fetal precursor cell transplantation must be carried out before the age of 4 years does not apply.
Down syndrome, genetic diseases in childhood, and various untreatable serious diseases of early age due to various prenatal and postnatal causes, birth injuries, mental retardation, failure to thrive, etc. have been treated by fetal precursor cell transplantation in clinical practice for 70+ years.
Down syndrome has been a shining example. Prof.Dr. F. Schmid published data about his personal treatment of over 3, 000 children with Down syndrome, as a result of which 25% of such children were able to attend regular schools in Germany.
The earlier in life fetal precursor cell transplantation was carried out, the better was the outcome, because cell transplantation cannot repair scar tissue. (The damaged brain tisssue is replaced after healing by connective tissue, i.e. scar.)
The same applies to the treatment of brain damage caused by events in utero, or during birth.
Based on our own clinical experience, when a newborn is born with a low Apgar score, a CT scan of the brain should be done at the age of 2 weeks, and if a 'peri-ventricular malacia' is found, which has generally been an accepted proof of serious abnormalities to be later on labelled as 'cerebral palsy' BCRO fetal precursor cell transplantation should be carried out without delay.
Once the child is diagnosed with a 'cerebral palsy' later on in life, any active treatment, including fetal precursor cell transplantation, will have lesser or no effect.
Parents of 'cerebral palsy' children spend enormous amount of time and money seeking treatment at the time when it is already too late.
This is tragic in particular for children with severe brain damage laying in a vegetable state in the chronic care hospitals.
At such an early age there is no need to implant fetal cell transplants directly into brain(!), a systemic application will work well, since
'homing', which attracts brain cells where they belong, i.e. into brain, even if implanted elsewhere in the body, is most active at an early age.
Our own published study of over 250 patients with Down syndrome, in which we evaluated mental and psychological functions of such children showed the following.
The percentage of younger Down syndrome children (up to 3.5 years of age) with mental development index of over 50 points increased from 17% before the first , to 58% after the first , and to 71% after the second .
The IQ in the older children (4 - 9 years of age) moved from the 25 to 49 points range to 50 - 69 points range, and the difference was statistically significant.
There was a decrease of hyperactivity, improvement of impaired concentration, lessened stereotypia and behavioral inertia, and improvement of speech expressivity observed already after the first , and the difference was statistically significant.
Volume of auditory/visual memory, productivity of thinking in categories, acoustic gnosis, and optic/spatial gnosis, were improved, but not significantly.
There was an improvement in motor area, particularly in fine coordinated movements, and in self-care habits, after .
There was absence of paroxysmal activity on EEG.
From 2007 on we have been treating classical Autism (as described by Kanner of Austria in 1943) with unexpected success, which has proved that autism is not a psychiatric disease but an organic brain damage, i.e. in autism there is one (or more) tiny inflammatory foci of par-encephalitis in the brain, too small to be identified even by the todays finest super modern diagnostic methods.
This was learned in Europe before WW2 and can be found in medical textbooks.
BCRO fetal precursor cell transplantation stops the pathologic electric discharges of the par-encephalitic focus in the brain, thereby allowing healing process to proceed. After healing, the re-education process to learn all the knowledge and life experience, that the autistic patient could not acquire in school and lost in life can begin.
BCRO fetal precursor cell transplantation has to be carried out immediately after the diagnosis of classical autism was made, because once the autistic patient loses contact with the world the subsequent loss of mental development, speech, education, learning of social skills, etc. is inevitable. The longer the patient remains in autistic condition, the longer it will take to return to normal life and reach normal milestones.
Since classical autism becomes apparent by the age of 2, maximum 3, years, BCRO fetal precursor cell transplantation should be done before attaining 4 years of age.
Human brain is the sole organ which continues its fetal development after birth, its maturation and differentiation! This makes central nervous system very vulnerable to noxious stimuli, but offers unique therapeutic possibilities. This therapeutic window of the first 3, maximum 4, years of life, must be taken advantage of, as wasting this opportunity means losing vitally important therapeutic chances!
Recently a term autism spectrum disorders appeared on the medical scene, that includes other diseases the list of which is constantly changing, all without any relationship to the classical autism, such as attention deficit disorder and attention deficit hyperactivity disorder, that are not diseases at all, but a label for poor teaching (so described by old teaching professionals themselves), and diseases as: Asperger syndrome, Retts syndrome, etc.
BCRO fetal precursor cell transplantation can be tried for treatment of Asperger syndrome, Retts syndrome, pervasive developmental disorder, Childhood disintegrative disorder, it will do no harm but we do not have enough experience to make any prediction as to the expected therapeutic success rate.
If you have any questions write to us: (firstname.lastname@example.org)
|FRAUD IN STEM CELL TRANSPLANTATION||WARRANTY/REPLACEMENT||DISCLAIMER||PRIVACY STATEMENT|
|Copyright Stem Cell Transplantation Ltd.|
|Updated: December 2018|